Clarification on the news article by Commercial Times

OBI Pharma Granted FDA Orphan Drug Designation for OBI-3424 for the Treatment of Acute Lymphoblastic Leukemia (ALL)
September 19, 2018
Correction on previous announcement: “Clarification on the news article by Commercial Times” to “United Daily News”
September 20, 2018
  1. Date of occurrence of the event: Sept 20, 2018
  2. Company name: OBI Pharma Inc.
  3. Relationship to the Company (please enter “head office” or “subsidiaries”): Head office
  4. Reciprocal shareholding ratios: N/A
  5. Name of mass media: Commercial Times
  6. Content reported: “…Biotech industry is profitable. OBI received Orphan Drug Designation…”
  7. Cause of occurrence: Clarification on news article
  8. Countermeasures: OBI-3424 was granted FDA Orphan Drug Designation for the treatment of Acute Lymphoblastic Leukemia (abbreviated as ALL). Please refer to MOPS announcement on Sept 19, 2018.
  9. Any other matters that need to be specified: new drug development is a long process associated with high costs. It is not a guaranteed success, which may increase the risk of investment. Investors shall make prudent judgments and investments.